FDA Approval Alert: The Need-to-Know | Osimertinib in Advanced EGFR-Mutated NSCLC

In September 2024, the FDA approved osimertinib for patients with EGFR exon 19 deletions or exon 21 L858R mutations in locally advanced, unresectable stage III non–small cell lung cancer as detected by an FDA-approved test.